Severity factors of dermatomyositis in Caribbean patients
Part of Bones, joints & muscles, Brain & nervous system, Skin clinical trials.
This study looks at what makes dermatomyositis more severe in people of Caribbean background living in Guadeloupe. By understanding these factors, doctors may better manage this rare muscle and skin disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 16 years old or older.
- You must have a confirmed diagnosis of dermatomyositis (a condition causing muscle weakness and skin rash).
- You or your parents or grandparents must be from the Caribbean (the islands).
- You must live in Guadeloupe.
- You must be covered by a social security health plan.
- You must not have started certain treatments (like IVIG, steroids, or immune-suppressing drugs) in the month before your dermatomyositis diagnosis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how severe dermatomyositis is in people who develop it as children or adults. It aims to better understand the disease and may help guide future treatments.
This trial tests an investigational drug called NM8074 for people with dermatomyositis, a condition that causes muscle weakness and skin rashes. The goal is to see if the drug can help control the disease.
This research study helps doctors better understand myositis—a group of rare diseases that cause muscle inflammation and weakness. Researchers collect blood samples, medical history, and sometimes muscle biopsies to learn more about what causes these conditions and how to treat them better.
This trial looks at a type of skin inflammation called panniculitis that can happen in people with dermatomyositis. The goal is to learn more about this condition so that better treatments can be developed.
This study tests a new immune therapy called CAR T-cells (KYV-101) for people with active, tough-to-treat dermatomyositis. It aims to see if the treatment is safe and can reduce muscle weakness and skin rash.
This study looks for environmental risk factors that may be linked to anti-synthetase syndrome, a type of inflammatory muscle disease. It compares people with the condition to carefully matched people without it, using questionnaires, blood samples, and lung imaging when needed.
Hear when a new Dermatomyositis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.